The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.
 
David F. McDermott
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; exelixis; Genentech/Roche; Merck; Novartis; Pfizer; X4 Pharma
Research Funding - Bristol-Myers Squibb; Prometheus (Inst)
 
Brian I. Rini
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche/Genentech; synthorx
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Merck; Pfizer
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Nizar M. Tannir
Honoraria - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Oncorena; Ono Pharmaceutical; Pfizer
Research Funding - Bristol-Myers Squibb; Epizyme; Exelixis; Mirati Therapeutics; Novartis
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Calithera Biosciences; Eisai; Exelixis; Nektar; Novartis; Onco Pharmaceuticals; Oncorena; Pfizer
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer
 
Christian K. Kollmannsberger
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Novartis; Pfizer
Travel, Accommodations, Expenses - Novartis; Pfizer
 
Hans J. Hammers
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; exelixis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Camillo Porta
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen; Novartis; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; EUSA Pharma; Janssen; Novartis; Pfizer
 
Saby George
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Exelixis; Genentech/Roche; Janssen Oncology; Novartis; Pfizer; Sanofi
Research Funding - Acceleron Pharma (Inst); Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
 
Frede Donskov
Research Funding - Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Howard Gurney
Honoraria - Pfizer
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst)
 
Marc-Oliver Grimm
Other Relationship - Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bayer Health; Bristol-Myers Squibb; Hexal; Intuitive Surgical; Ipsen; Janssen-Cilag; MSD; Novartis; Ono Pharmaceutical; Pfizer; Sanofi/Aventis
 
Michael Roger Harrison
Consulting or Advisory Role - Argos Therapeutics; AstraZeneca; Bayer; Exelixis; Fujifilm; Genentech; Janssen Oncology; Pfizer; Sanofi
Speakers' Bureau - Exelixis; Genentech
Research Funding - Argos Therapeutics (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Medivation/Astellas (Inst); Merck (Inst); Pfizer (Inst)
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Shuo Yang
Employment - Bristol-Myers Squibb
 
Jennifer Johansen
Employment - Bristol-Myers Squibb
 
Sumati Rao
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Sabeen Fatima Mekan
Employment - Bristol-Myers Squibb
 
Michael Rael
Employment - Evidera
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen